With the introduction of new drugs with different mechanisms of action, multiple myeloma (MM) patients' outcomes have improved. However, the efficacy seen in clinical trials is often not seen in real-world settings and data on the effectiveness of MM therapies are needed. INSIGHT MM is a prospective, global, non-interventional, observational study that is enrolling approximately 4200 patients with newly diagnosed or relapsed/refractory MM, making it the largest study of its kind to date. The study aims to describe contemporary, real-world patterns of patient characteristics, clinical disease presentation, therapies chosen, clinical outcomes (response, treatment duration, time-to-nexttherapy, progression-free and overall survival), safety, healthcare resource utilization and quality of life. One interim analysis has been conducted to date; current accrual is approximately 3094 patients.
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To describe contemporary, real-world patterns of patient characteristics, clinical disease presentation, therapeutic regimen chosen, and clinical outcomes in multiple myeloma (MM) on a regional and global scale
To evaluate the safety and effectiveness of current therapies, the impact of MM on patients' quality of life and healthcare resource utilization (HRU), and the associations between patient characteristics, clinical disease presentation, therapeutic patterns, and clinical outcomes Multiple myeloma (MM) is the second most common hematologic malignancy, with an estimated incidence of 30,770 new cases and 12,770 deaths in the USA in 2018 [1] and an estimated 48,300 new cases in Europe in 2018 [2] . Survival rates have improved dramatically over the past 20 years; the United States National Cancer Institute SEER program estimated a 5-year relative survival of 29.3% for patients with MM who were diagnosed in 1990-1992, compared with 52.4% for those diagnosed in 2008-2014 [3] . In the UK, the estimated 5-year net survival for male and female patients diagnosed with MM between 2011 and 2015, was 51.9% and 50.8%, respectively, compared with 22.4% and 21.9%, respectively, for those diagnosed between 1990 and 1991 [4, 5] . In a Swedish population-based study, the 5-year relative survival rate improved from 0.28 to 0.41 for patients diagnosed with MM in 1973-1982 and 2003-2013 , respectively [6] . Furthermore, MM is two-to threefold more common in African-Americans (AAs) compared with European-Americans and in AAs it is the most common hematologic malignancy, a disparity that may be due to a different underlying genetic predisposition between these groups [7] . This improvement in outcomes for patients with MM has been attributed to the introduction of high-dose chemotherapy plus autologous stem cell transplant, as well as the development, approval and use of multiple new drugs and combination regimens in both the newly diagnosed MM (NDMM) and relapsed/refractory MM (RRMM) settings [8] . Over the past 20 years, 12 therapies and agents with different mechanisms of action, including immunomodulatory drugs, proteasome inhibitors (PIs), monoclonal antibodies (mAbs), as well as a histone deacetylase (HDAC) inhibitor, a Bcl-2 inhibitor and a selective inhibitor of nuclear export (SINE) agent, have been approved or have entered advanced phases of clinical testing, thus expanding the potential treatment armamentarium against MM [8, 9] . A list of key agents and regimens that are approved/recommended [10] [11] [12] or have been/are being investigated in clinical trials is reported in Tables 1, 2 and Figure 1 . This is not an exhaustive list but provides an overview of the many agents and regimens available for MM treatment.
Mirroring the emergence of new therapies with different mechanisms of action, MM treatment strategies have evolved, with more complex combination regimens being used, such as triplets versus doublets [13] . Additionally, there is now an increased use of continuous or long-term maintenance therapy approaches, which have been shown in clinical trials to prolong survival and delay disease progression, compared with fixed-duration or short-term treatment plans [14] .
As MM treatment options become more complex, choosing an appropriate agent or combination of agents in routine clinical practice becomes increasingly challenging [15] . Although recommendations and guidelines for treatment sequencing are available, these vary between countries and global regions [10, 12] , and different agents [9, 10, 11, 12, 41, 59] and regimens are approved in different countries; as a result, there is currently no uniform, global standard-of-care treatment for patients with MM, in either the NDMM or RRMM setting.
Background & rationale
In this context, the availability of real-world data is increasingly important to our understanding of global variations in treatment practices and the impact of anti-MM therapies in the real-world setting. Despite the efficacy improvements seen with anti-MM agents in the context of clinical trials, the same results are not always achieved in the real-world setting in terms of the effectiveness of a regimen, with poorer long-term outcomes reported for real-world patients versus clinical trial-enrolled patients [16, 17] . This discrepancy is likely due to multiple factors, including the rigorous study protocols followed in clinical trials [16] and the strict eligibility criteria used to select patients for enrollment [18] . For example, of the patients enrolled in the CONNECT-MM registry, 40% were found to be ineligible for inclusion in randomized controlled clinical trials (RCT) based on common exclusion criteria (M-protein ≤1.0 g/dl, creatinine >2.5 mg/dl, low absolute neutrophil count [≤1.5 × 10 9 /l] and low hemoglobin [≤8 g/dl]) [19] . Importantly, RCT-ineligible patients had a significantly lower 3-year survival rate than RCT-eligible patients (63% vs 70%; p < 0.05) [19] , suggesting that clinical trial findings may not translate to the overall MM population. In the CoMMpass registry, 22% of patients met the study definition of ineligibility for clinical trials [20] . A recent analysis estimated that only 25%, 35%, 41% and 47%, respectively, of USA real-world patients meet the eligibility criterial of the ASPIRE (NCT01080391), TOURMALINE-MM1 (NCT01564537), ELOQUENT-2 (NCT01239797) and POLLUX (NCT02076009) RCTs, investigating lenalidomide/dexamethasone-based triplets in RRMM [21] . Additionally, specific patient populations, such as elderly or frail patients, patients with comorbidities, advanced disease or aggressive and rapidly progressing disease, as well as some ethnic or racial minorities, are typically under-represented in clinical trials [19, 22, 23] , and their omission may therefore contribute to the gap between efficacy and effectiveness. Other factors such as toxicities, the burden of long-term therapy, differences in clinical care and practice patterns between treatment centers, as well as access to and cost of therapy in real-world settings may also play a role in the observed gap between trial-based and real-world outcomes [16, 24] . This gap between efficacy and effectiveness highlights the importance of collecting real-world data on MM disease characteristics, treatment patterns and outcomes for anti-MM agents on a country-specific and global level from unselected patient populations, to better inform treatment decisions in everyday clinical practice. Real-world data for agents such as PIs, immunomodulatory drugs, mAbs and HDAC inhibitors are emerging in MM [17, [25] [26] [27] [28] [29] , and a variety of methods have been used in the past approximately 10 years to collect and analyze real-world datasets, including pharmaceutical company-sponsored prospective/retrospective registries and formal observational studies (Table 3) , as well as national registries, administrative claims studies and retrospective chart reviews [16] .
Nevertheless, currently available data on clinical presentation, treatment patterns and outcomes for MM in the community setting at a global level, as well as on patient-reported aspects such as health-related quality of life (HRQoL), are limited. Therefore, additional real-world data are needed to bridge the gap between clinical trial efficacy and routine clinical practice effectiveness of anti-MM agents and regimens, so that treating physicians can effectively incorporate these new therapies into existing treatment algorithms and ultimately improve patient outcomes [30] .
INSIGHT MM study
Here we describe the design and rationale for the INSIGHT MM study (NCT02761187), a large, global, prospective, non-interventional, observational study of patients with NDMM or RRMM. This is the largest and the first truly global study of its kind to date, incorporating multiyear enrollment and follow-up.
Objectives
INSIGHT MM is enrolling both NDMM and RRMM patients, and the primary objective of the study is to gain a better understanding of patient and disease characteristics both at diagnosis and at relapse, treatment regimens prescribed and associated patient outcomes in the real-world setting. Specific areas of interest include demographic data, symptoms at presentation, disease characteristics at baseline and at relapse, and assessment of the impact of MM and treatment on patients' HRQoL and on healthcare resource utilization (HRU). Other objectives include: assessment of patient outcomes based on cohort (NDMM or RRMM), type of treatment facility (academic vs community, with academic centers being defined as those associated with a university or academic hospital), and region or country of enrollment; evaluation of the treatment regimens used; assessment of the factors associated with initiation or modification of treatment; evaluation of the associations between patient characteristics, clinical disease presentation, therapeutic regimen chosen and clinical outcomes. future science group www.futuremedicine.com
Study design
INSIGHT MM is a non-interventional study and no study drug or medications are being provided. Patients are to be treated according to the current standard of care at the study site and no changes in patients' treatment or management are required. Each patient's care is determined entirely by his/her healthcare provider. However, patients are required to complete patient self-reported outcomes (PRO) questionnaires during routine on-site clinic visits. While participating in this study, patients can also be enrolled in another observational or non-blinded, interventional study that does not prohibit participation in this trial. Eligible patients are being identified and followed prospectively. Information on patient characteristics, diagnosis and previous treatment is collected from hospital or clinic records at baseline; MM-specific disease management, safety and outcomes data are obtained during routine on-site clinic visits on a quarterly basis. A global steering committee has been established to provide support for the study, to advise on protocol development, study conduct and activity, and to ensure that scientific validity and rigor are maintained throughout the study. The steering committee comprises 20 treating physicians from around the globe (ten from the USA, ten from elsewhere), who are considered experts in the field of MM treatment, as well as two patient representatives. Inclusion of the two patient representatives ensures that the patients' perspective is incorporated in every aspect of the study, from study design and data collection, to the publication of the results and the communication of the findings to the wider MM community; in addition, involvement of the patient representatives ensures that patients' concerns and needs are considered throughout the conduct of the study.
The study is being conducted in accordance with local ethical guidelines, European directives on protection of human patients in research, the Declaration of Helsinki, the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance Guidelines, Good Pharmacoepidemiology Practice Guidelines and other local or national specific, relevant guidelines, laws or regulations. All patients are required to provide written informed consent before data collection, including authorization to use their patient medical records.
Eligibility criteria
The study is enrolling NDMM and RRMM patients of ≥18 years of age. Patients with NDMM must enroll within 3 months of treatment initiation. Patients with RRMM could have received up to three prior lines of therapy before entering the study. All patients are required to have documented information available on the month and year of diagnosis, criteria met for diagnosis, stage, including International Staging System (ISS) and revised-ISS (R-ISS), prior therapies received, including duration of each prior line of treatment, whether they underwent stem cell transplant and received consolidation/maintenance therapy and whether they received any investigational therapy. In addition, all patients must be willing and able to complete the PRO instruments and sign the informed consent. Patients are excluded from the study if they report to a study site only for a second opinion, if they are participating in another trial that prohibits enrollment in this study or if they do not attend the clinic frequently enough to allow for quarterly completion of the electronic case report forms (eCRFs).
Planned sample size, study period, & selection of study sites
The target enrollment for this study is approximately 4200 patients, with approximately equal numbers of NDMM and RRMM patients to be enrolled. Patients are being enrolled over a period of approximately 3 years and will be evaluated and followed-up prospectively for a minimum of 5 years, until death, withdrawal of consent or end of study. The study is expected to end after all study patients have either completed a minimum of 5 years of follow-up, have been lost to follow-up or have died prior to study end. Patients are followed-up longitudinally and assessed on a quarterly basis to document changes in disease and/or lines of therapy.
Patients are being recruited from study sites around the world, including North America, South America, Europe and Asia; 15 countries are participating ( Figure 2 ). All participating sites are required to provide care for MM patients and to appoint a healthcare provider who agrees to oversee the study conduct and ensure that the protocol is followed correctly.
Variables, outcome measures & end points
Measures collected during the study include assessment of patient demographics and disease characteristics, including presence of co-morbidities, disease symptoms at presentation, Eastern Cooperative Oncology Group performance status, ISS or R-ISS disease stage and cytogenetic risk. Data on patients' frailty status, including Charlson comorbidity index, Katz index of independence in activities of daily living and Lawton instrumental activities of daily living scale, are also being collected, and may serve as an important predictor of outcomes and toxicities. Details of therapeutic regimens received, including duration of each line of therapy and whether patients have received prior stem cell transplant, are being collected and summarized. Outcome measures include overall survival (OS), progression-free survival (PFS), response per International Myeloma Working Group criteria [31] and time-to-next therapy (TTNT). Table 4 lists variables collected during the study. These include documentation of treatment combinations prescribed, duration of treatment, sequencing of therapies, retreatment and use of continuous versus fixed-duration therapy, and if a patient has received therapy as part of a clinical trial. Patient outcomes including best response, OS, PFS and TTNT, associated with treatment regimens are being documented prospectively from study entry. Changes in treatment patterns over time are being documented by collecting information on initial and subsequent drug regimens and classes received during the study for all patients, as they move through lines of therapy. In addition, factors associated with treatment initiation and reasons for not receiving therapy are being collected. Modifications to treatment, including reasons for changes to drug, dose, schedule and duration, are also being collected. The impact of MM and treatment on patients' HRQoL is being assessed through the use of validated PRO instruments, and data on HRU are being collected. Safety is being investigated throughout the study by collecting information on adverse events (AEs) and serious AEs leading to temporary or permanent treatment discontinuation or to drug modifications, as well as by monitoring the frequency of second primary malignancies. Information on reasons for dose modification and permanent drug discontinuation that are being collected include: AEs/toxicity, relapse due to biochemical or clinical progression, remission or death, planned therapy change or patient/family preference.
Study assessments
Details of study assessments are reported in Table 4 . Briefly, information on patient demographics, disease characteristics and medical history prior to study inclusion, including prior anti-MM therapies received, is collected at baseline. Disease management, effectiveness of treatment and safety are being assessed quarterly.
PROs are being collected at study inclusion and quarterly thereafter using paper forms during routine clinic visits. HRQoL is being assessed based on: • Nine items from the Treatment Satisfaction Questionnaire for Medication 9 (TSQM-9) covering the domains of effectiveness, convenience and global satisfaction [33] .
HRU is also assessed quarterly, including rates of inpatient and intensive care unit admissions, reasons for admissions, length of stay, outpatient clinic visits and emergency room visits.
To ensure accuracy and completeness of the data, both an automatic query and a manual query process are utilized. Automatic queries are intended to resolve insufficient data entries or missed fields. Manual queries are conducted on flagged, new and changed data. Data reviews are conducted on a monthly basis at a minimum. In addition, the study coordinator and principal healthcare provider at each participating site are responsible for the quality and consistency of data in the study and will maintain accurate electronic case report forms and patient medical charts as part of the case histories.
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Statistics
The planned sample size of approximately 4200 patients is intended to provide enough patients to characterize treatment in a broad population, and to maintain a reasonable level of statistical power to detect differences between subgroups. A sample size of 268 in each of any two comparison subgroups will have at least 80% power to detect a difference between two proportions, given the true difference is at least 12%. However, no formal hypothesis will be tested in this study and all analyses are exploratory in nature. All enrolled patients are considered for inclusion in the analyses. Due to the observational nature of the study, and to address potential confounding factors and bias, adjusted regression models will be used to determine the associations between: (1) MM therapy regimens, disease attributes (e.g., disease stage and risk) and patient factors (e.g., age and frailty) and (2) clinical outcomes, HRU and HRQoL. The final analysis will take place approximately 5 years after enrollment of the last patient. Interim data summaries and formal interim analyses are being conducted as appropriate while the study is ongoing, to understand patients' initial clinical presentations at diagnosis and relapse and the effectiveness of therapies in the real world [34, 35] .
Discussion
While clinical trial efficacy is critical for the MM treatment decision-making process, real-world data are becoming increasingly important as they can inform clinicians about treatment effectiveness and toxicity in a broader patient population treated outside of controlled clinical trials, with the ultimate goal of improving patients' care and outcomes. Numerous MM observational and national registry studies have been conducted or are ongoing/being planned worldwide (Table 3 and Richardson et al. 2018 [16] ), and evidence from these studies may help in elucidating the critical factors contributing to the discrepancies reported between clinical trial efficacy and realworld effectiveness as well as guiding treatment choices.
While data from several MM observational and national registry studies are already available (Table 3 and Richardson et al. 2018 [16] ), INSIGHT MM is the first non-interventional, observational study that is truly global in nature, with patients being recruited from centers in 15 countries in North America, Central and South America, Europe and Asia (Figure 2 ). Another unique aspect of this study is the open, collaborative nature of the project and the willingness to share data beyond the investigators who participate in the trial, thereby providing a mechanism for the submission of research ideas from the broader MM community. With an increasing number of real-world MM registries being initiated in multiple geographical regions, the INSIGHT MM steering committee plans to explore the power of collating datasets and conducting collaborative analyses with country-specific MM registries and other observational studies, including the Czech Registry of Monoclonal Gammopathies [27, 36] and the Australian and New Zealand Myeloma and Related Diseases Registry [37] . Partnerships between registries will increase the power of the analyses, provide a snapshot of MM treatment patterns and outcomes on a global scale, allow exploration of a wider range of clinically relevant questions as well as provide results with higher accuracy and generalizability to the whole MM population.
Inclusion of HRQoL end points in clinical trials can provide a more comprehensive evaluation of treatment outcomes by incorporating the patient's perspective. The collection of PRO data to evaluate patients' HRQoL is a particular strength of INSIGHT MM, highlighting the patient-centric approach taken in the development of this study and the growing importance of PROs in real-world studies in MM (Table 3 ). In addition, several recent pivotal Phase III trials of anti-MM agents have incorporated HRQoL analyses and demonstrated that HRQoL benefits may be associated with improved outcomes [32, 38, 39] . Treatment-related factors, including toxicities, disease symptoms and the burden of treatment and symptom/side-effect management, can negatively affect patients' HRQoL [24] ; therefore, it is particularly important to maintain HRQoL during MM therapy, especially for patients receiving long-term/maintenance therapy. In the INSIGHT MM study, symptoms of peripheral neuropathy, one of the most important complications of MM which can adversely impact on patients' HRQoL [40] , are reported by patients through the EORTC QLQ-MY20 questionnaire. Additionally, patient satisfaction with their medication and patients' perspectives on treatment convenience will be assessed via the TSQM-9 questionnaire to provide information on treatment adherence [33] ; this is a critical challenge for patients receiving long-term/maintenance treatment with agents requiring repeated dosing and frequent clinic visits, which can impose a substantial burden [24] .
Real-world data for anti-MM agents are already beginning to emerge [17, [25] [26] [27] [28] [29] but, thanks to INSIGHT MM and other registries, in the future these data will be much more extensive and robust as more patients are enrolled, and it will become clearer which attributes, including which therapies, are having the greatest impact on patients' outcomes and HRQoL.
Conclusion
Two data analyses of the INSIGHT MM study have been reported to date. The first included 1000 patients enrolled from 13 countries (535 NDMM, 465 RRMM), and the second analysis included the first 1056 NDMM patients enrolled from 14 countries [34, 35] . Both analyses highlighted marked regional differences in real-world treatment patterns in NDMM/RRMM, potentially due to differences in drug availability and treatment guidelines at academic versus community centers [34, 35] . Results from a second interim analysis, which will include approximately 3000 patients, are awaited with interest.
In conclusion, these interim data analyses and, ultimately, the final study findings will provide comprehensive insights into patient and disease characteristics, treatment patterns, outcomes, patients' HRQoL and safety of contemporary treatment approaches for NDMM and RRMM patients in community and academic settings worldwide. These data will be of substantial importance to the MM community, as they have the potential to improve our understanding of the factors contributing to the discrepancies between clinical trial efficacy and real-world effectiveness of anti-MM agents and regimens, and thereby improve patients' outcomes. future science group www.futuremedicine.com
Executive summary

